Findings

What do systematic reviews say?

7 questions · 7 findings · 4 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 28.6%GRADE not reported 0 · 0%Very low 2 · 28.6%Low 1 · 14.3%Moderate 2 · 28.6%High 0 · 0%

Anticoagulant vs different dose of the same anticoagulant

Deep vein thrombosis · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anticoagulant vs antiplatelet agent

Deep vein thrombosis · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anticoagulant vs placebo or no treatment

Deep vein thrombosis · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant showed no clear difference in deep vein thrombosis compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 1.02 [0.3, 3.46]
3 studies · 1009 participants
Moderate

Anticoagulant vs no treatment

Deep vein thrombosis · people hospitalised with COVID‐19

It is very uncertain whether anticoagulants changes deep vein thrombosis compared with no treatment (very low certainty).

1 finding from 1 review

Anticoagulants for people hospitalised with COVID‐19: a rapid review 2022 · Cochrane Headline outcomes only
RR 5.67 [1.3, 24.7]
1 study · 1403 participants
Very low

Higher‐dose anticoagulants vs lower‐dose anticoagulants

Deep vein thrombosis · people hospitalised with COVID‐19

Higher‐dose anticoagulants showed no clear difference in deep vein thrombosis compared with lower‐dose anticoagulants (low certainty).

1 finding from 1 review

Anticoagulants for people hospitalised with COVID‐19: a rapid review 2022 · Cochrane Headline outcomes only
RR 1.08 [0.57, 2.03]
4 studies · 3422 participants
Low

Anticoagulant vs control

Deep vein thrombosis · acute presumed ischaemic stroke

It is very uncertain whether summary of findings table ‐ Anticoagulant changes deep vein thrombosis during treatment period compared with control (very low certainty).

1 finding from 1 review

Anticoagulants for acute ischaemic stroke 2021 · Cochrane Headline outcomes only
OR 0.21 [0.15, 0.29]
10 studies · 916 participants
Very low

Direct oral anticoagulant (DOAC) prophylaxis vs no prophylaxis

Symptomatic DVT · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in symptomatic deep vein thrombosis compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation 2021 · Cochrane Headline outcomes only
RR 0.61 [0.31, 1.21]
3 studies · 1440 participants
Moderate